These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34897643)

  • 21. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
    Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
    Expert Opin Drug Discov; 2020 Sep; 15(9):993-1004. PubMed ID: 32450711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
    Svetel M; Tomić A; Kresojević N; Kostić V
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
    Żegleń M; Śladowska K; Kawalec P; Brzostek T
    J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
    [No Abstract]   [Full Text] [Related]  

  • 27. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opicapone for the treatment of Parkinson's disease: a review.
    Feldman M; Margolesky J
    Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
    [No Abstract]   [Full Text] [Related]  

  • 29. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
    Annus Á; Vécsei L
    Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
    Hauser RA; Videnovic A; Soares-da-Silva P; Liang GS; Olson K; Jen E; Rocha JF; Klepitskaya O
    Parkinsonism Relat Disord; 2024 Jun; 123():106971. PubMed ID: 38631081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
    JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
    Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
    Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opicapone for the treatment of Parkinson's disease: an update.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2019 Dec; 20(18):2201-2207. PubMed ID: 31670988
    [No Abstract]   [Full Text] [Related]  

  • 34. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.
    Schofield C; Chaudhuri KR; Carroll C; Sharma JC; Pavese N; Evans J; Foltynie T; Reichmann H; Zurowska L; Soares-da-Silva P; Lees A
    Neurodegener Dis Manag; 2022 Apr; 12(2):77-91. PubMed ID: 35313124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opicapone for the treatment of Parkinson's disease.
    Rodrigues FB; Ferreira JJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.